News | October 08, 2010

Study Shows Bivalirudin Improves Survival in AMI

October 8, 2010 – New data from the HORIZONS-AMI trial shows that administering the anticoagulant bivalirudin (Angiomax) enhances survival in heart attack patients undergoing angioplasty after three years. The results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium in Washington, D.C.

The study compared bivalirudin to the use of heparin plus a GP IIb/IIIa inhibitor. The data also showed that a drug-eluting stent (paclitaxel) was as safe and more effective than a bare-metal stent.

“The results at three years, representing the final report from the HORIZONS-AMI trial, are consistent with and extend the two-year data that we reported last year at TCT,” said Gregg W. Stone, M.D., professor of medicine at Columbia University College of Physicians and Surgeons, director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York Presbyterian Hospital/Columbia University Medical Center and co-director of the medical research and education division at the Cardiovascular Research Foundation. Stone is the principal investigator of the HORIZONS-AMI trial.

“The data demonstrate that use of bivalirudin alone, as opposed to a combination of heparin and a GP IIb/IIIa inhibitor, can save lives,” Stone said. “In addition, a significant reduction in second heart attacks has emerged over time in patients treated with bivalirudin.”

After three years, treatment with bivalirudin resulted in:

• A 36 percent reduction in major bleeding and a 24 percent reduction in re-infarction, with nonsignificantly different rates of stent thrombosis, target vessel revascularization (TVR) and stroke.

• A 44 percent reduction in cardiac mortality and a 25 percent reduction in all-cause mortality, the latter representing 18 lives saved per 1,000 patients treated with bivalirudin.

In addition, at three years, the implantation of a paclitaxel-eluting stent resulted in:

• A significant 40 percent reduction in ischemic target lesion revascularization (TLR), with preservation of the gains achieved within the first year over time.

• Nonsignificantly different rates of all-cause and cardiac mortality, re-infarction and stent thrombosis.

For more information: www.crf.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Overlay Init